Sexual dysfunction in women using major tranquilizers

Degen, Kathleen

doi:10.1016/s0033-3182(82)73071-3

Cited by 31 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Estimates of the prevalence of galactorrhea vary from 10-50%. A well-conducted study found that 28/150 women (19%) developed galactorrhea within 75 days of commencing conventional antipsychotic treatment [40]. In this study, only 8 women reported the symptom on their own to the clinician, illustrating that symptomatic hyperprolactinemia is often unrecognized or under-reported.…”

Section: Introductionmentioning

confidence: 73%

“…Priapism, a sustained painful erection that can result in permanent impotence, has also been reported [68,69]. Women report decreased libido and orgasmic dysfunction, including difficulty achieving orgasm, changes in the quality of orgasm and anorgasmia [40,59]. Women may also experience dysparenuria secondary to vaginal atrophy and dryness.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)

et al. 2013

View full text Add to dashboard Cite

Prolactin elevations occur in people treated with antipsychotic medications and are often much higher in women than in men. Hyperprolactinemia is known to cause amenorrhea, oligomenorrhea, galactorrhea and gynecomastia in females and is also associated with sexual dysfunction and bone loss. These side effects increase risk of antipsychotic nonadherence and suicide and pose significant problems in the long term management of women with schizophrenia. In this manuscript, we review the literature on prolactin; its physiology, plasma levels, side effects and strategies for treatment. We also present the rationale and protocol for an ongoing clinical trial to treat symptomatic hyperprolactinemia in premenopausal women with schizophrenia. More attention and focus are needed to address these significant side effects and help the field better personalize the treatment of women with schizophrenia.

show abstract

Section: Introductionmentioning

confidence: 73%

Section: Introductionmentioning

confidence: 99%

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Surprisingly few studies investigated women only. Kathleen Degen, a New York Professor of Psychiatry, explored the literature on desire, excitement and orgasm in women, and argued that studies generally focused on male sexual performance (Degen 1982). High levels of orgasmic dysfunction were seen in women taking Fluphenazine depot injections.…”

Section: Medicationmentioning

confidence: 99%

Exploring sexual and relationship possibilities for people with psychosis – a review of the literature

McCann

2003

Psychiatric Ment Health Nurs

View full text Add to dashboard Cite

This review examines the literature on sex and relationship issues in the context of serious and persistent mental health problems. It identifies gaps in the research and highlights key issues needing further investigation. The available published documents have been identified, which contain information, ideas, data and evidence on the topic. A critical analysis of the subject, through the examination of the various documents, is provided. The main themes that emerged included HIV/AIDS, medication and sexual dysfunction, sexuality needs, intimate relationships, family planning, policies and sex education. Several subthemes are discussed and include needs assessment, stigma and loneliness. The key findings highlight the lack of systematic studies in the UK, especially regarding the subjective views of patients in determining need and the subsequent development of appropriate plans of care. The author argues that future mental health research needs to go beyond investigating perceived 'risky' behaviours and should include potential therapeutic responses in all areas of sexuality. Further recommendations are made in terms of nurse education particularly the inclusion of psychosexual aspects in future pre- and postregistration curricula. This paper may be of interest to service users, mental health practitioners working alongside people with serious and persistent mental health problems as well as educators, researchers and policy makers.

show abstract

“…(iii) Thioridazine was probably one of the fi rst antipsychotic drugs identifi ed as having the ability to cause delayed ejaculation [ 90 ] . (iv) There are many case reports on antipsychoticinduced anorgasmia: among these, the most frequently cited antipsychotic is thioridazine [ 89 ] , followed by trifl uoperazine [ 91 ] . (v) Priapism is a possible side eff ect of all antipsychotic drugs [ 92 ] , particularly for phenothiazines (chlorpromazine, fl uphenazine and thioridazine), although more recently isolated cases have been reported with aripiprazole [ 93 ] , clozapine, fl upenthixol [ 89 ] , olanzapine, quetiapine [ 94 , 95 ] , risperidone [ 25 ] and ziprasidone [ 95 -97 ] .…”

Section: Antipsychotics and Sexual Dysfunctionmentioning

confidence: 99%

Untitled

2013

Pharmacopsychiatry

View full text Add to dashboard Cite

▼Sexual dysfunction is a potential side eff ect of antipsychotic drugs: this article presents a critical review of the current literature. Although many studies have been published on the subject, only some used a validated sexual function rating scale and most lacked either a baseline or placebo control or both. In addition, many of the studies on sexual dysfunction associated with antipsychotic medication are limited by other methodological fl aws. However, there is consistent evidence to suggest that a large number of antipsychotic drugs adversely aff ect one or more of the 3 phases of sexual response (desire, arousal and orgasm). Among the antipsychotics, the so called "prolactin-raising" are probably most associated with sexual dysfunction, even if further studies to confi rm this are needed: the reviewed literature shows no consistent evidence that any one antipsychotic drug has a signifi cantly superior side eff ect profi le over another and current information on this topic is often based on methodologically weak research. Clinicians must be aware of drug-induced sexual dysfunction, since its presence can have important consequences for clinical management and compliance.This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.

show abstract

Sexual dysfunction in women using major tranquilizers

Cited by 31 publications

References 8 publications

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)

Exploring sexual and relationship possibilities for people with psychosis – a review of the literature

Untitled

Contact Info

Product

Resources

About